Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  TEL AVIV STOCK EXCHANGE  >  Compugen Ltd.    CGEN   IL0010852080

COMPUGEN LTD. (CGEN)
My previous session
Most popular
  Report  
Delayed Quote. Delayed  - 01/17 10:24:38 am
1099 ILa   +1.76%
2018COMPUGEN LTD. : quaterly earnings release
2018COMPUGEN LTD. : half-yearly earnings release
2017COMPUGEN LTD. : quaterly earnings release
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsRevisions 
Quotes 5-day view   Delayed Quote. Delayed Tel Aviv Stock Exchange
01/13/2019 01/14/2019 01/15/2019 01/16/2019 01/17/2019 Date
1067(c) 1058(c) 1049(c) 1080(c) 1095(c) Last
68 260 31 776 27 903 11 846 26 900 Volume
+4.30% -0.84% -0.85% +2.96% +1.39% Change
More quotes
Financials (ILS)
Sales 2018 65,8 M
EBIT 2018 -90,0 M
Net income 2018 -88,3 M
Finance 2018 155 M
Yield 2018 -
Sales 2019 33,2 M
EBIT 2019 -142 M
Net income 2019 -141 M
Debt 2019 17,2 M
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales2018 8,25x
EV / Sales2019 21,5x
Capitalization 697 M
More Financials
Company
Compugen Ltd. is a therapeutic discovery company. The Company focuses on infrastructure to discover drug targets and develop therapeutics. The Company is engaged in the research, development and commercialization of therapeutic and product candidates. The Company's pipeline primarily consists of... 
More about the company
Surperformance© ratings of Compugen Ltd.
Trading Rating : - Investor Rating :
More Ratings
Latest news on COMPUGEN LTD.
01/15COMPUGEN : s Phase 1 Trial of COM701 Featured as a Trial-in-Progress at The ASCO..
AQ
2018New Research Coverage Highlights Vulcan Materials, Cimpress N.V, Asterias Bio..
AQ
2018COMPUGEN : 3Q Earnings Snapshot
AQ
2018COMPUGEN LTD. : quaterly earnings release
2018COMPUGEN THIRD QUARTER 2018 CONFEREN : 30 am et
PR
2018COMPUGEN : BMS and Compugen join forces on solid tumour clinical trials
AQ
2018BRISTOL MYERS SQUIBB : BMS invests $12m in cancer immunotherapy tie-up with Comp..
AQ
2018COMPUGEN : BMS invests $12m in Israeli Compugen for tumor collaboration
AQ
2018BRISTOL MYERS SQUIBB : Myers embraces a possible checkpoint collaborator, snaggi..
AQ
2018BRISTOL MYERS SQUIBB : and Compugen Announce Clinical Collaboration to Evaluate ..
AQ
More news
Analyst Recommendations on COMPUGEN LTD.
More recommendations
Sector news : Biotechnology & Medical Research - NEC
01/18Samsung Bioepis biosimilar to Roche's Herceptin wins FDA nod
RE
01/08NEKTAR THERAPEUTICS : Shares Up Tuesday as Gilead Collaboration Announced -- Mar..
DJ
01/08GlaxoSmithKline to look for early-stage assets - CEO
RE
01/08Lilly's Deal Boosts Its Cancer Arsenal -- WSJ
DJ
01/07Eli Lilly to Buy Loxo Oncology in $8 Billion Deal -- 5th Update
DJ
More sector news : Biotechnology & Medical Research - NEC
Chart COMPUGEN LTD.
Duration : Period :
Compugen Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends COMPUGEN LTD.
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
EPS Revisions
Managers
NameTitle
Anat Cohen-Dayag President, Chief Executive Officer & Director
Paul Jai Sekhri Chairman
Ari Krashin Chief Operating & Financial Officer
Zurit Levine Vice President-Research & Discovery
Henry Adewoye Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
COMPUGEN LTD.29.27%189
IQVIA HOLDINGS INC6.82%25 444
CELLTRION, INC.--.--%22 863
LONZA GROUP8.95%20 746
INCYTE CORPORATION23.32%16 688
SEATTLE GENETICS, INC.29.92%11 878